# A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

> **NCT06004336** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 144 (estimated)

## Conditions studied

- Oligometastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT06004336
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004336, "A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06004336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*